Finally, as suggested by previous studies5,6, we show that prior lines of therapy, and in particular selective pressure from treatment with ipilimumab alters both the tumor and TME characteristics thus masking the response to second-line anti-PD-1. This evidence concerns the gene PDCD1 and neoplasm.